Blood Res.  2022 Apr;57(S1):S112-S119. 10.5045/br.2022.2022038.

Recent advances in treatments of adult immune thrombocytopenia

• Kim DS

• KMID: 2529316
• DOI: http://doi.org/10.5045/br.2022.2022038

Abstract

Immune thrombocytopenia (ITP) is isolated thrombocytopenia characterized by autoimmune-mediated disruption of platelet without other etiologies. Treatments for chronic ITP consist of corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, thrombopoietin receptor agonists, immunosuppressants and splenectomy. Although current therapies are effective in over two-thirds of patients, some patients are refractory to therapies or fail to achieve long-term responses. Recently, great advance has been made in identifying various mechanisms involved in ITP pathogenesis, and new treatments targeting these pathways are being developed. Novel agents such as splenic tyrosine kinase inhibitor, Bruton kinase inhibitor, plasma cell targeting therapies, neonatal Fc receptor inhibitor, platelet desialylation inhibitor, and inhibition of the classical complement pathway are expected to be effective for ITP treatment. This review summarizes current strategies and emerging therapies of ITP.

Keyword

Immune thrombocytopenia; Platelet; Treatment; Pathogenesis; Thrombopoietin receptor agonist